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Retrospective database studies of PAH using US payer claims data have limitations 
due to lack of specific ICD-9 codes for PAH and ability to identify patient severity. 
Previous studies used an algorithm which includes patients with non-specific PH 
codes, along with a claim for an advanced PAH drug therapy. This study attempts 
to validate the algorithm and identify patient disease severity through linkage to 
data abstracted from medical charts. Objectives: To evaluate validity of a retro-
spective review of payer database along with chart abstraction for confirmation of 
PAH diagnosis and identification of World Health Organization Functional Class 
(FC). MethOds: Medicare patients who received an (1) endothelin-receptor antago-
nist, phosphodiesterase type 5 inhibitor, or prostacyclin AND (2) had a diagnosis of 
pulmonary hypertension, other chronic pulmonary hypertension or chronic pulmo-
nary heart disease OR (3) medical claim indicating right heart catheterization (RHC) 
were identified from pharmacy and medical claims data. A random sub-sample of 
110 patients was chosen and the providers contacted to provide medical charts. 
Charts were reviewed to abstract data indicating PAH diagnosis, FC, and/or symp-
toms, diagnostic tests, and treatments to enable classification. Results: Of 110 
charts requested, 41 were received and abstracted. Twenty-one charts (51%) came 
from a specialist. All 41 charts documented a confirmed diagnosis of PAH. Of those, 
18 (44%) explicitly identified PAH class. Physical symptoms were reported, with dysp-
nea (66%) being most frequent, while walk test results, documentation of RHC and 
pulmonary diagnostic tests were reported in less than 20% of cases. cOnclusiOns: 
The identification algorithm successfully identified diagnosed, confirmed cases 
of PAH. Refinements to provider selection algorithm could result in an increase in 
provider response rate, charts with documented FC and overall chart data quality.
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Objectives: We conducted a systematic review to appraise the methodological 
quality of controlled clinical trials evaluating the efficacy and safety of Chinese 
herbal medicine (CHM) patients with rheumatoid arthritis (RA). MethOds: We 
searched electronic databases (Medline, EMBASE, The Cochrane Library, and Web 
of Science) from inception until May 2014. Study selection was performed by 2 
independent reviewers. The methodological quality of the trials was assessed using 
the Cochrane risk of bias tool for randomized trials and Newcastle Ottawa Scale 
for controlled non-randomized studies. Results: 54 studies were included (51 
randomized trials; 3 non-randomized studies) evaluating 7,792 patients. Only one 
study was conducted in the US, the remaining in China. There were 3,446 patients 
receiving CHM. In the control groups 2,283 patients received a disease modifying 
anti-rheumatic drug (DMARD), 182 non-steroidal anti-inflammatory drugs (NSAIDs), 
and 164 inert placebo. For the randomized studies, when evaluating selection bias 
54% of the studies were judged to have an adequate random sequence generation, 
but 77% had inadequate allocation concealment. 79% had a high risk of performance 
bias (not blinding participants and/or personnel) and detection bias was unclear 
in 56% of the studies; 62% of the studies reported how missing data was handled, 
therefore attrition bias was judged to be low. In 87% no disclosure of interest or 
source of founding was reported. For non-randomized studies, all the studies were 
representative of RA patients, had an adequate ascertainment of intervention with 
comparable groups, but only one demonstrated that the outcome of interest was not 
present at start of study or provided the rate of lost to follow-up. cOnclusiOns: 
Studies evaluating CHM often fail to meet expected methodological criteria, and 
high quality evidence is lacking. Future studies of CHM should be methodologically 
robust and adhere to reporting guidelines such as the CONSORT statement for TCM.
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Objectives: Health economists are being encouraged to use routine datasets for 
resource-use measurement and costing purposes in economic evaluations alongside 
clinical trials to reduce research burden. The Hospital Episode Statistics (HES) data-
set, which records all NHS hospital-based activity in England, is one such dataset. 
However, its validity for research purposes has not been established. This study 
aims to assess the validity of the HES outpatient dataset. MethOds: Men who 
died of, or with, prostate cancer were selected from a prostate-cancer screening 
trial (CAP, Cluster randomised triAl of testing for Prostate cancer). Details of visits 
that took place after 1/4/2003 to hospital outpatient departments for conditions 
related to prostate cancer were extracted from medical records (MR). Data from the 
HES outpatient dataset were obtained for the same men. Appointments for visits 
extracted from MR were sought in the HES dataset. The matching procedure was 
repeated for periods before and after 1/4/2008 (when the dataset was accredited as 
a national statistic). Results: 4922 outpatient appointments were extracted from 
MR for 370 men between 2003 and 2012. 4086 appointments recorded in MR were 
identified in the HES dataset (83.0%; 95%CI 81.9–84.1). Allowing a +/-2 day tolerance 
for the appointment date resulted in a slight improvement to 4171 (84.7%; 95%CI 
83.7–85.7) matches (p= 0.5). For appointments occurring when the dataset was con-
sidered experimental (prior to 1/4/2008), 2194/2754 (79.7%; 95%CI 78.1–81.2) matches 
were observed, while 1892/2168 (87.3%; 95%CI 85.8–88.6) appointments occurring 
after 1/4/2008 were identified (p= 0.03). cOnclusiOns: The HES outpatient data-
Objectives: This research will present the Bayesian decision analytic framework 
for late phase study simulation and calculation of chance of study success applied 
to optimal target population and study design. A real-world example in mother-
to-child transmission of HIV conducted in Thailand will be used to illustrate the 
concepts throughout. MethOds: Predictive models describing virtual cohorts over 
time under various care strategies can be informed via Bayesian inference using all 
relevant data available on associations between population characteristics, relative 
drug efficacy, drug uses and design parameters. In the proposed example, historical 
transmission data from 3,876 Thai women were modeled via mixed-effect logistic 
regression adjusted for viral load, gestational age, CD4 count at delivery and infant 
treatment duration. Viral load was described as an exponential function of prophy-
laxis duration. Monte Carlo simulations were used to predict intrapartum transmission 
rates with and without single dose nevirapine (sdNVP) added to the standard of care 
(antenatal prophylaxis), and predict chance of success of a naturalistic Phase IIIb 
study in Thailand under various assumptions on target population and adaptive study 
design. Results: In women with short prophylaxis durations (< 8-weeks) estimate of 
intrapartum transmission rate was 2.6% (95%-Credibility Interval= 0.5%-9.2%) with the 
standard of care and 0.8% (95%-CI= 0.1%-2.9%) with sdNVP added to standard care, 
corresponding to a risk ratio of RR= 3.9 (95%-PI= 2.1-9.7). Study simulations showed 
that a single-arm study with stopping rules at N= 58, 118, 275, and 410 has 78% (resp. 
68%) probability of evidencing RR> 1.3 (resp. RR> 2). cOnclusiOns: When the associa-
tion between outcomes, design parameters and the main effectiveness drivers can 
be informed by historical data, Bayesian predictive models can be powerful decision 
support tools for optimal target population and late-phase or pragmatic study design.
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Objectives: The aim of the study was to assess the delayed-time effect on survival 
of the immunotherapy with a cancer vaccine by comparing the conventional logrank 
test vs a weighted logrank in presence of non-proportional hazards. MethOds: 
Data from a multicenter, open-label and randomized phase III clinical trial with 
an EGF-based cancer vaccine in advanced NSCLC. The diagnosis of the delayed-
time effect was done and the time-delay was estimated. The non-proportional 
hazards were also confirmed and tested delayed effect on survival of the treat-
ment. Weighted logrank tests was applied and the results were compared with 
those obtained using the conventional logrank test. The R software was used in 
the analysis. Results: The time-delay was estimated in 28 months and a signifi-
cant effect after this time was verified. The proportional hazard assumption was 
not satisfied. The median survival for the vaccinated arm was 10.37 months vs. 
8.93 months for non-vaccinated arm. The difference was statistically significant by 
weighted logrank (p= 0.04) and the conventional logrank test does not detect this dif-
ference. cOnclusiOns: Weighted logrank is substantially more efficient than the 
conventional logrank statistic in those situations in which non-proportional hazards 
are foreseen. This analysis is recommended for immunotherapies where the appear-
ance of a late biological effect is displayed several months after randomization.
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Objectives: The degree to which predefined risk factor (RF) changes alter long-term 
clinical and cost outcomes in the IMS-CORE-Diabetes-Model (CDM) was reported 
in earlier publications. Since this time the CDM has undergone a series of updates 
including the inclusion of recently published UKPDS-82 risk equations (UK-82-RE). The 
objective of this study was to project the lifetime benefits and total lifetime costs (TLC) 
associated with a range of selected RF changes opposing results from CDM projections 
utilizing UKPDS-68 risk equations (UK-68-RE) vs. UK-82-RE. MethOds: The CDM was 
applied to project the lifetime benefits (life years (LYs), quality adjusted life years 
(QALYs)) and TLC (£GBP) associated with baseline RF changes for HbA1c, body-mass-
index (BMI), systolic blood pressure (SBP), high-density-lipoprotein (HDL) and low-den-
sity-lipoprotein (LDL). A intermediate risk type-2 diabetes cohort (age 52 years, HbA1c 
8%, SBP 140 mm-Hg, BMI 30 Kg/m2, HDL 50 mg/dl and LDL 150 mg/dl) was projected 
over lifetime to explore the sensitivity of undiscounted LYs, QALYs and TLC for selected 
RF ranges (A1c+/-2%, SBP+/-20 mmHg, BMI+/-2 Kg/m2, HDL+/-10 mg/dl, LDL+/-20 mg/
dl). Linear regression models were fitted to assess the degree of end point sensitivity 
per unit RF change. Results: When UK-68-RE were applied, projected changes in 
benefits were 0.264, 0.094, 0.050, -0.611 and 0.162 LYs and 0.288, 0.111, 0.123, -0.358, and 
0.113 QALYs associated with unit RF reductions of 1% point (A1c), 10 mm-HG (SBP), 
1 KG/m2 (BMI), 10 mg/dl (HDL) and 10 mg/dl (LDL), respectively. This compared 
to changes of 0.161, 0.079, 0.053, -0.262, 0.311 (LYs) and 0.215, 0.099,0. 116, -0.178, 
0.208 (QALYs) utilizing UK-82-RE. TLC decreased by £1’105, £298, £115, £680 and £38 
utilizing UK-68-RE and £1’073, £309, -£71, -£221, -£7 with UK-82-RE. cOnclusiOns: 
The degree to which RF changes are translated into benefits and costs may change 
considerably dependent on the choice of selected risk equations.
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